Agilent Buys Seahorse for $235 Million
Seahorse’s XF line of analyzers measures cell metabolism, a key research field for drug development, allowing in vitro, real-time, simultaneous measurements of mitochondrial respiration and glycolysis. Seahorse is one of the few firms that provides dedicated biosensor systems for this application area. According to healthcarenews.com, Seahorse’s revenues totaled $13 million in 2009.
Santa Clara, CA and Billerica, MA 9/9/15—Agilent Technologies has definitively agreed to acquire Seahorse Bioscience for $235 million in cash. Seahorse provides instruments and assay kits for measuring cell metabolism and bioenergetics. Founded in 2001 and employing nearly 200 people, Seahorse is expected to generate $49 million in fiscal 2015 revenues. “Seahorse Bioscience’s unique technology is the perfect complement to Agilent’s market leading separations and mass spectrometry solutions, in particular for metabolomics research and disease research in pharma,” stated Patrick Kaltenbach, president of Agilent’s Life Sciences and Applied Markets Group. To be completed by November 1, the acquisition is expected to be accretive in fiscal 2016 to Agilent EPS and will be financed by debt.
